It will be another three months before the US Food and Drug Administration (FDA) is ready to give its verdict on the drug ruxolitinib from Incyte. The review period for the drug ruxolitinib has been extended until Sept. 21, according a company press release.
Ruxolitinib is administered as a topical treatment for atopical dermatitis, and it is in the class of drugs known as JAK-inhibitors.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.